Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 101 Carcinoma, Non-Small-Cell Lung 88 Carcinoma, Renal Cell 54 Neoplasm Metastasis 37 Squamous Cell Carcinoma of Head and Neck 32 Colorectal Neoplasms 32 Carcinoma, Hepatocellular 32 Lung Neoplasms 31 Hodgkin Disease 25 Neoplasms 24 Urinary Bladder Neoplasms 21 Pancreatic Neoplasms 21 Carcinoma, Transitional Cell 20 Breast Neoplasms 19 Stomach Neoplasms 17 Brain Neoplasms 17 Prostatic Neoplasms 16 Small Cell Lung Carcinoma 15 Sarcoma 15 Multiple Myeloma 14 Head and Neck Neoplasms 14 Esophageal Neoplasms 14 Glioblastoma 11 Uterine Cervical Neoplasms 10 Rectal Neoplasms 10 Neuroendocrine Tumors 10 Lymphoma 10 Recurrence 9 Ovarian Neoplasms 9 Nasopharyngeal Carcinoma 9

Interventions

Sunitinib 5 pembrolizumab 4 Paclitaxel 4 Carboplatin 4 Radiotherapy 3 Cyclophosphamide 3 Cisplatin 3 selinexor 2 lenvatinib 2 Taxes 2 Ramucirumab 2 Octreotide 2 N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2 Methylprednisolone 2 Erlotinib Hydrochloride 2 Chemoradiotherapy 2 zimberelimab 1 saracatinib 1 regorafenib 1 epacadostat 1 envafolimab 1 belinostat 1 avelumab 1 atezolizumab 1 amrubicin 1 alovudine 1 TP protocol 1 Radiofrequency Ablation 1 Radiation Dose Hypofractionation 1 Prednisone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Thymoma × Nivolumab × Clear all

NCT03134118 2026-05-15

NIVOTHYM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Active not recruiting

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡